# US 8,277,841 B2 · Polyamide rate-modulated monolithic drug delivery system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,841 B2
- Document ID: US8277841B2
- Status: Granted
- Kind: B2
- Application number: 12/528,175
- Filed: 2008-02-22
- Published: 2010-12-23
- Granted: 2012-10-02
- Earliest claimed: 2007-02-23
- Assignees: University of The Witwatersand, Johannesburg
- Inventors: Oluwatoyin Ayotomilola Kolawole; Viness Pillay; Yahya Essop Choonara
- Web page: https://patentgrep.com/patent/US8277841B2

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/2045: {Polyamides; Polyaminoacids, e.g. polylysine}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to a polyamide rate-modulated monolithic drug delivery system comprising at least one active compound and a biodegradable and biocompatible polyamide polymer. The polymer is selected for delivering, in use, the active compound, within a predetermined time frame depending on the biodegradable properties of the polymer, to a target organism or organisms. In one embodiment of the invention the polymer is modified by salting-out or crosslinking the polymeric material to achieve the desired biodegradability characteristics and, consequently, to control the release of the active compound.

## Claims

### Claim 1

A polyamide rate-modulated monolithic drug delivery system comprising at least one active compound and a biodegradable and biocompatible synthetic aliphatic polyamide polymer selected for delivering the active compound within a predetermined time frame to a target organism.

### Claim 2 (depends on 1)

The polyamide rate-modulated monolithic drug delivery system of claim 1, wherein the active compound is a pharmaceutical compound for application to humans or animals.

### Claim 3 (depends on 1)

The polyamide rate-modulated monolithic drug delivery system of claim 1, wherein the active compound is a biocidal composition for use in controlling animal and/or plant pests.

### Claim 4 (depends on 1)

The polyamide rate-modulated monolithic drug delivery system of claim 1, wherein the polymer is modified by salting-out or crosslinking the polymeric material to achieve the desired biodegradability characteristics and to control the release of the active compound.

### Claim 5 (depends on 2)

The polyamide rate-modulated monolithic drug delivery system of claim 2, wherein the polymer and active compound are present in a dosage form suitable for oral administration.

### Claim 6 (depends on 5)

The polyamide rate-modulated monolithic drug delivery system of claim 5, wherein the dosage form is a tablet.

### Claim 7 (depends on 2)

The polyamide rate-modulated monolithic drug delivery system of claim 2, wherein the polymer and active compound are present in a dosage form suitable for implantation in a human or animal body.

### Claim 8 (depends on 3)

The polyamide rate-modulated monolithic drug delivery system of claim 3, wherein the polymer and active compound are present in a dosage form suitable for application by spraying.

### Claim 9 (depends on 3)

The polyamide rate-modulated monolithic drug delivery system of claim 3, wherein the polymer and active compound are present in a dosage form suitable for application by dusting.

### Claim 10 (depends on 3)

The polyamide rate-modulated monolithic drug delivery system of claim 3, wherein the polymer and active compound are in the form of a flowable powder.

### Claim 11 (depends on 1)

The polyamide rate-modulated monolithic drug delivery system of claim 1, wherein the polymer and the active compound form a matrix which biodegrades at a predetermined rate to release the active compound over a predetermined period of time.

### Claim 12 (depends on 11)

The polyamide rate-modulated monolithic drug delivery system of claim 11, wherein a metal hydroxide is added to the matrix to reinforce the matrix integrity and to limit outward diffusion of the active compound.

### Claim 13 (depends on 12)

The polyamide rate-modulated monolithic drug delivery system of claim 12, wherein the metal hydroxide is sodium hydroxide.

### Claim 14 (depends on 11)

The polyamide rate-modulated monolithic drug delivery system of claim 11, wherein an organic solvent is added to the matrix to reinforce the matrix integrity and to limit outward diffusion of the active compound.

### Claim 15 (depends on 14)

The polyamide rate-modulated monolithic drug delivery system of claim 14, wherein the organic solvent is cyclohexane.

### Claim 16 (depends on 1)

The polyamide rate-modulated monolithic drug delivery system of claim 1, wherein the synthetic aliphatic polyamide is a 6,10 variant thereof.

### Claim 17 (depends on 1)

The polyamide rate-modulated monolithic drug delivery system of claim 1, wherein the physicochemical and physicomechanical properties of the polymer are enhanced by optimizing the stoichiometry of a monomer composition, solvent phase modifiers and/or conditions of polymeric synthesis.

### Claim 18 (depends on 17)

The polyamide rate-modulated monolithic drug delivery system of claim 17, wherein the physicochemical and physicomechanical properties of the polymer are enhanced by optimizing its molecular mass, crystallinity, porosity, melting temperature, solubility, matrix resilience, matrix hardness and deformation energy or combination thereof.

### Claim 19 (depends on 16)

The rate-modulated monolithic drug delivery system of claim 16, wherein the polymer is enhanced by a modified interfacial polymerization approach in order to optimize the release of an active compound in terms of the order and release rate.

### Claim 20 (depends on 19)

The rate-modulated monolithic drug delivery system of claim 19, wherein the synthetic aliphatic polyamide 6,10 variant has had its physicochemical and physicomechanical properties optimized as a result of modifying the stoichiometry of monomer composition, solvent phase modifiers and the conditions of polymeric synthesis.

### Claim 21 (depends on 20)

The rate-modulated monolithic drug delivery system of claim 20, wherein the physicochemical and physicomechanical properties of the polyamide have been optimized by altering one or more of its molecular mass, crystallinity, porosity, melting temperature, solubility, matrix resilience, matrix hardness and deformation energy.

### Claim 22 (depends on 16)

The rate-modulated monolithic drug delivery system of claim 16, wherein solvent phase modifiers are added to the polymer to alter the solvent pH and polarity to enhance the matrix integrity of the rate-modulated monolithic drug delivery system, and also influencing the polymeric diffusivity.

### Claim 23 (depends on 22)

The rate-modulated monolithic drug delivery system of claim 22, wherein the solvent phase modifier is a metal hydroxide.

### Claim 24 (depends on 23)

The rate-modulated monolithic drug delivery system of claim 23, wherein the metal hydroxide is sodium hydroxide.

### Claim 25 (depends on 22)

The rate-modulated monolithic drug delivery system of claim 22, wherein the solvent phase modifier is an organic solvent.

### Claim 26 (depends on 25)

The rate-modulated monolithic drug delivery system of claim 25, wherein the organic solvent is cyclohexane.
